Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study

Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H, Posevitz-Fejfar A

Research article (journal) | Peer reviewed

Details about the publication

JournalNeurology
Volume83
Issue2
StatusPublished
Release year2014
Language in which the publication is writtenEnglish

Authors from the University of Münster

Breuer, Johanna
Posevitz Fejfar, Anita
Schneider-Hohendorf, Tilman
Schwab, Nicholas Christopher
Schwab, Nicholas Christopher
Wiendl, Heinz Siegfried